Search Results

Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.

AnPac Bio-Medical Science Co., Ltd. announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares, pre-funded warrants to purchase ADSs and warrants to purchase ADSs.

AnPac Bio-Medical Science Co., Ltd. announced that it has entered into a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares, pre-funded warrants to purchase ADSs and warrants to purchase ADSs in a registered direct offering.

Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, reported its financial results for the fiscal year ended December 31, 2023.

AnPac Bio-Medical Science Co., Ltd. announced that on March 31, 2023, the Company entered into an asset purchase agreement with Easy Hundred Inc., a U.S.-based e-commerce company in the foodservice industry, through which the Company will acquire certain fixed assets of Easy Hundred and Easy Hundred’s intellectual property relating to ez100, 2Supply and 100WAY.

AnPac Bio-Medical Science Co., Ltd. (the “Company”) (NASDAQ: ANPC) announced the closing of the acquisition of GISN (HK) LIMITED (“GISN”), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises.

AnPac Bio-Medical Science Co., Ltd. announced that on March 22, 2023, the Company has been notified by the Nasdaq Hearings Panel (“Panel”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s request for continued listing on The Capital Market has been granted.

AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC) announced that in December 2022 and January 2023, the Company signed definitive investment agreements with several third party investors.

AriBio Co., Ltd. announces the expansion of testing for Alzheimer’s disease by entering into a strategic collaboration with Kentucky Clinical Trial Laboratory for the testing of cerebral spinal fluid to accurately and efficiently aid in the diagnosis of Alzheimer’s disease using the Lumipulse® system from FujireBio.

AnPac Bio-Medical Science Co., Ltd. announced today that it has received the first payment in late February 2023 from a Malaysian customer who had signed a US$1.5 million purchase contract for AnPac Bio’s Model AP9080 cancer detection devices.